Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatography assay for the novel antitumour agent CT2584 in human plasma.
A HPLC assay and solid-phase extraction technique from human plasma has been developed and validated for the novel anticancer agent CT2584, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, which has recently completed a phase I trial at the Christie Hospital, Manchester under the auspices of the CRC phase I/II committee. Following addition of CT2576, 1-(11-octylamino-10-hydroxylundecyl)-3,7-dimethylxanthine, as internal standard, a solid-phase extraction cartridge (100 mg cyanopropyl) was used to isolate the drug CT2584 from human plasma. Analysis was performed by reversed-phase chromatography. CT2576 was used as internal standard at a concentration of 4 microg ml(-1) for the quantification of CT2584 from plasma for the duration of this work. The lower limit of quantification for the drug CT2584 in buffer using this assay was found to be 0.0122 microM (0.008 microg ml(-1)) and 0.048 microM (0.027 microg ml(-1)) when extracted from human plasma.
CRC Section of Drug Development and Imaging, Paterson Institute for Cancer Research, Manchester, UK. pkhan@picr.man.ac.uk
P
P
Khan
S
S
Abbas
S
S
Cheeseman
M
M
Ranson
A T
AT
McGown
D000970:Antineoplastic Agents / Q000097:blood*; D002021:Buffers; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007202:Indicators and Reagents; D009369:Neoplasms / Q000097:blood; D015203:Reproducibility of Results; D014970:Xanthines / Q000097:blood*
D000970:Antineoplastic Agents; D002021:Buffers; D007202:Indicators and Reagents; D014970:Xanthines; C106011:CT 2584